This bill mandates that various health insurance providers in New Jersey, including health, hospital, and medical service corporations, as well as health maintenance organizations, must cover expenses related to the prescription and purchase of buprenorphine and buprenorphine/naloxone for pain treatment. Importantly, the bill stipulates that this coverage cannot be subjected to step therapy or fail-first protocols, which are often used by insurers to require patients to try less effective or more addictive medications before accessing preferred treatments.

The legislation aims to enhance access to buprenorphine and buprenorphine/naloxone, which are recognized for their lower potential for addiction compared to other pain management options. By eliminating the barriers associated with step therapy and fail-first protocols, the bill seeks to ensure that patients with chronic pain can receive these medications more readily, thereby promoting safer and more effective pain management practices. The act is set to take effect 90 days after its enactment.